New shot could simplify prostate cancer treatment

NCT ID NCT07005154

Recruiting now Disease control Sponsor: Astellas Pharma Global Development, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 6 times

Summary

This phase 2 trial tests ASP5541, a new injectable form of the hormone therapy abiraterone, in men with advanced prostate cancer that has spread. The study compares ASP5541 (given every 12 weeks) to daily abiraterone pills, both with or without steroids. About 218 men with metastatic hormone-sensitive or castration-resistant prostate cancer will take part to see if the injection works as well or better and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASP5541 (an injectable form of abiraterone acetate)
What this could lead to: If it works, this could offer a more convenient, longer-lasting treatment option for advanced prostate cancer, reducing the need for daily pills.
What could go wrong: This is a phase 2 trial, so it's still early. The drug may not work better than current treatments, and side effects like hormone-related issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PROSTATE CANCER

Contacts and locations

Locations

Associated Urological Specialists
RECRUITING

Chicago Ridge, Illinois, 60415, United States
Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Clearview Cancer Institute
RECRUITING

Huntsville, Alabama, 35805, United States
H. Lee Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Harasanshin Hospital
RECRUITING

Fukuoka, Japan
Huai'an First People's Hospital
RECRUITING

Huaian, 211731, China
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, Japan
New Mexico Oncology Hematology Consultants
RECRUITING

Albuquerque, New Mexico, 87109, United States
Nippon Medical School Hospital
RECRUITING

Bunkyo-ku, Tokyo, Japan
NorthShore University HealthSystem
RECRUITING

Evanston, Illinois, 60201, United States
Ochsner Health - Ochsner Medical Center - New Orleans
RECRUITING

New Orleans, Louisiana, 70121, United States
Osaka International Cancer Institute
RECRUITING

Osaka, Japan
PanOncology Trials
RECRUITING

San Juan, Puerto Rico
Renji Hospital Shanghai Jiaotong Univ School of Medicine
RECRUITING

Shanghai, 200127, China
Sharp HealthCare - Sharp Memorial Hospital
RECRUITING

San Diego, California, 92123, United States
Shizuoka Cancer Center
RECRUITING

Sunto-gun, Shizuoka, Japan
Site DE49001
RECRUITING

Heinsberg, Germany
Site DE49004
RECRUITING

Nürtingen, Baden-Wurttemberg, Germany
Site ES34001
RECRUITING

Madrid, Spain
Site ES34003
RECRUITING

Santiago de Compostela, Spain
Site ES34005
RECRUITING

Barcelona, Spain
Site ES34006
RECRUITING

Barcelona, Catalonia, Spain
Site ES34008
RECRUITING

Barcelona, Spain
Site FR33003
RECRUITING

Bordeaux, France
Site FR33004
RECRUITING

Strasbourg, France
Site FR33006
RECRUITING

Paris, France
Site FR33008
RECRUITING

Lille, France
Site FR33009
RECRUITING

Le Mans, France
Site GB44003
RECRUITING

London, United Kingdom
Site IT39003
RECRUITING

Trento, Italy
Site IT39004
RECRUITING

Milan, Italy
Site IT39005
RECRUITING

Roma, Italy
Site IT39006
RECRUITING

Milan, Italy
Site KR82002
RECRUITING

Seoul, South Korea
Site KR82003
RECRUITING

Seoul, South Korea
Site KR82004
RECRUITING

Seoul, South Korea
Site KR82006
RECRUITING

Daegu, South Korea
Site KR82007
RECRUITING

Seoul, South Korea
Site KR82008
RECRUITING

Gwangju, South Korea
Site PL48005
RECRUITING

Mysłowice, Poland
Site PL48007
RECRUITING

Gliwice, Poland
Site PL48008
RECRUITING

Otwock, Poland
Site TW88602
RECRUITING

Taipei, Taiwan
Site TW88603
RECRUITING

Kaohsiung City, Taiwan
Solaris Health - The Urology Group
RECRUITING

Cincinnati, Ohio, 45212, United States
Subei People's Hospital
RECRUITING

Yangzhou, Jiangsu, 225001, China
Tennessee Oncology Nashville
RECRUITING

Nashville, Tennessee, 37203, United States
The Cancer Institute Hospital of JFCR
RECRUITING

Koto, Tokyo, Japan
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
The Second Hospital of Tianjin Medical University
RECRUITING

Tianjin, Tianjin Municipality, 300211, China
UW Health Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22908-07, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.